Adicet Bio, Inc. (ACET)
| Market Cap | 82.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -116.80M |
| Shares Out | 10.75M |
| EPS (ttm) | -16.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,518 |
| Open | 7.78 |
| Previous Close | 7.93 |
| Day's Range | 7.55 - 7.92 |
| 52-Week Range | 6.01 - 17.44 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 48.33 (+528.48%) |
| Earnings Date | May 6, 2026 |
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price target is $48.33, which is an increase of 528.48% from the latest price.
News
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Announces Reverse Stock Split
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Gamma delta CAR T therapies show strong safety and efficacy in autoimmune diseases, with ongoing responses and immune reset in LN and SLE. Multiple data readouts and regulatory milestones are expected next year, supported by robust manufacturing and a solid cash runway.
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2
Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in aut...
Adicet Bio Transcript: Study Update
Phase 1 results for ADI-001 in LN and SLE showed rapid, durable clinical responses, robust immune reset, and a favorable safety profile, with all patients discontinuing immunosuppressants and most achieving complete or partial renal response. The off-the-shelf, outpatient potential differentiates ADI-001 from autologous therapies, supporting plans for a pivotal single-arm trial in 2026.
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Off-the-shelf gamma delta 1 CAR T therapies show strong safety and efficacy in autoimmune diseases, with ADI-001 targeting multiple indications and aiming for outpatient use. Key clinical data are expected this year, and a PSMA-targeted oncology program is advancing.
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Off-the-shelf Gamma-delta CAR-T therapies show promise for autoimmune diseases, offering safety, convenience, and robust B cell depletion. Initial clinical data for SLE and LN are expected soon, with endpoints focused on remission and steroid reduction. Manufacturing supports large-scale dosing.
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio Transcript: Jefferies Global Healthcare Conference 2025
The session highlighted a diversified pipeline of off-the-shelf γδ one CAR T-cell therapies in autoimmune and oncology, with key data readouts expected in the second half of the year. Programs target high unmet needs, leveraging unique cell properties for efficacy and safety.
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio Transcript: The Citizens JMP Life Sciences Conference 2025
Gamma delta CAR T cell therapies are advancing in both autoimmune and solid tumor indications, with off-the-shelf convenience, strong safety, and tissue targeting. Key data from lupus nephritis, SLE, and RCC programs are expected in the second half, supported by robust financials and positive regulatory engagement.
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...